fluorouracil has been researched along with Shock, Septic in 5 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 9.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 5.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Patients with malignancy may present with acute circulatory compromise requiring ICU monitoring and care." | 2.41 | Circulatory shock. ( Bogolioubov, A; Groeger, JS; Keefe, DL, 2001) |
| "Pseudomembranous colitis is frequently associated with antibiotics and more rarely with chemotherapeutic agents such as 5-fluorouracil." | 1.33 | Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. ( Aranda Aguilar, E; de la Haba Rodríguez, JR; Gómez España, MA; Méndez Vidal, MJ; Morales Chamorro, R; Rubio Pérez, MJ; Serrano Blanch, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Houssany, S | 1 |
| Renner, J | 1 |
| Boutonnet, M | 1 |
| Peigne, V | 1 |
| Soler, C | 1 |
| Kuehr, T | 1 |
| Ruff, P | 1 |
| Rapoport, BL | 1 |
| Falk, S | 1 |
| Daniel, F | 1 |
| Jacobs, C | 1 |
| Davidson, N | 1 |
| Thaler, J | 1 |
| Boussard, B | 1 |
| Carmichael, J | 1 |
| Morales Chamorro, R | 1 |
| Serrano Blanch, R | 1 |
| Méndez Vidal, MJ | 1 |
| Gómez España, MA | 1 |
| Rubio Pérez, MJ | 1 |
| de la Haba Rodríguez, JR | 1 |
| Aranda Aguilar, E | 1 |
| Köhne, CH | 1 |
| De Greve, J | 1 |
| Hartmann, JT | 1 |
| Lang, I | 1 |
| Vergauwe, P | 1 |
| Becker, K | 1 |
| Braumann, D | 1 |
| Joosens, E | 1 |
| Müller, L | 1 |
| Janssens, J | 1 |
| Bokemeyer, C | 1 |
| Reimer, P | 1 |
| Link, H | 1 |
| Späth-Schwalbe, E | 1 |
| Wilke, HJ | 1 |
| Bleiberg, H | 1 |
| Van Den Brande, J | 1 |
| Debois, M | 1 |
| Bethe, U | 1 |
| Van Cutsem, E | 1 |
| Bogolioubov, A | 1 |
| Keefe, DL | 1 |
| Groeger, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181] | Phase 3 | 86 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Shock, Septic
| Article | Year |
|---|---|
Circulatory shock.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Carcinoid Tu | 2001 |
2 trials available for fluorouracil and Shock, Septic
| Article | Year |
|---|---|
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot | 2008 |
2 other studies available for fluorouracil and Shock, Septic
| Article | Year |
|---|---|
[Septic shock and Tissierella praeacuta].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cholecystitis | 2016 |
Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clostridioides difficile; Dihydropyrimidine Dehydro | 2005 |